Baird analyst Michael Ulz said his outlook on Tesaro (NASDAQ: TSRO) is unchanged following approval of Clovis's Rubraca.Ulz commented, "Approval ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE